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Palliative radiation therapy is a mainstay in the management 
of symptoms among patients with advanced and metastatic 
cancers. However, there is a latent period between the 
delivery of therapy and the hoped for response to it. As such, 
patients should not receive therapy unless an estimate of 
their expected survival is first made. Acute side effects 
cannot be justified unless there is a reasonable expectation 
that patients may live long enough to benefit from therapy. 
This presentation will summarise the difficulties radiation 
oncologists have had historically with predicting survival for 
their patients, it will highlight studies of palliative radiation 
therapy among patients nearing the end of life, it will 
present prognostic models from the literature that are most 
applicable to those practicing palliative radiation therapy, 
and it will focus on topics that are in need of and are well 
suited to future research in this important area of study.     
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The primary goal of screening is the early detection of 
asymptomatic, previously unrecognized malignancy when 
treatment is more effective than if it were instituted after 
development of signs or symptoms. Screening for metastatic 
disease has historically been used to narrow therapeutic 
options and avoid futile interventions. But in the 
oligometastatic era - where the separation between curative- 
and palliative-intent radiotherapy is becoming less distinct – 
case-finding for the purposes of radical treatment of low 
volume distant metastases is increasingly common, despite 
the lack of clarity regarding the impact on clinical outcomes, 
quality of life and health care costs. Systematic risk-
stratification would ideally enable the selective utilization of 
scarce resources, avoiding test-related complications along 
with delays in initiation of treatment awaiting results which 
have little likelihood of altering management in the majority 
of patients. Potential benefits of different modalities will be 
reviewed, as well as issues to be considered in defining both 
an appropriate target population and screening approach. 
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In most departments, up to 40% of all radiation treatments 
are given with palliative intent. This includes treatment of 
metastatic sites of disease and locally advanced primary 
disease. Over the last 10 years with the availability of new 
technologies, we have seen an increasing complexity of 
palliative radiation treatments particularly in the setting of 
oligometastatic disease. Coupled with this, advances in 
systemic therapies in many disease sites have translated into 
patients with metastatic disease living longer. Unlike curative 
intent treatment which is largely protocol driven, palliative 
intent treatment requires knowledge of a multitude of 
patient, disease and treatment factors and the ability to 
accurately predict prognosis in order to individualise 
fractionation and treatment technique. Palliative 
radiotherapy is becoming recognised internationally as a sub 
speciality and it is becoming increasingly important that we 
recognise the need for formalised palliative care training 
within our speciality. Through international collaboration we 
can develop core competencies for our trainees, encourage 
palliative radiotherapy rotations and fellowship 
opportunities, and foster enthusiasm for palliative 
radiotherapy research in the future striving to deliver 
evidence-based, convenient and effective treatment for 
patients with the fewest possible side effects.  
 
 




SP-0102   
On-board MR image guidance for adaptive therapy  
R. Kashani1, J. Victoria2, D. Yang1, T. Zhao1, O. Green1, V. 
Rodriguez1, L. Olsen1, H. Wooten1, H. Li1, L. Santanam1, J. 
Michalski1, J. Dempsey2, S. Mutic1, J. Olsen1 
1Washington University School of Medicine, Radiation 
Oncology, St. Louis, USA  
2ViewRay Inc., Science, Cleveland, USA  
 
The concept of magnetic resonance image-guided radiation 
therapy (MR-IGRT) has been under development for the past 
few years, with the first clinical system implemented and in 
use since January of 2014. This system consists of a split 
0.35T MR scanner straddled by three 60Co sources mounted on 
a ring gantry. The on-board MR shares an isocenter with the 
RT system and is capable of capturing high resolution 
volumetric images of the patient in the treatment position, 
as well as real-time planar cine images during treatment 
delivery.  
The availability of on-board MR images offers the capability 
to visualize soft tissue for better localization, as well as 
potential treatment adaptation based on the geometry of the 
day. The MR-IGRT system implemented in our clinic has an 
integrated treatment planning system with fast dose re-
optimization, and dose calculation which allows modification 
of structure contours, followed by re-planning while the 
patient remains in the treatment position.  
While the topic of online adaptive therapy has been of 
significant interest in research studies over the past two 
decades, the clinical implementation has been straggling 
behind due to the stringent system requirements necessary to 
make the process clinically realistic.  
Here we report on the clinical implementation of the first 
online adaptive therapy system, the workflow and staffing 
considerations, patient specific quality assurance, and the 
achievable overall treatment times from initial patient setup 
to completion of the treatment.  
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The morphology of cervical cancer referred for definitive 
radio-chemotherapy varies considerably ranging from 
expansive tumours confined to the cervix (stage IB) to 
irregular and infiltrating tumours involving the parametria 
(stage IIB), further to  the pelvic wall (stage IIIB), or to the 
distal part of the vagina (stage IIIA). Bladder and rectum may 
also be involved (stage IVA) as well as the corpus uteri. In 
addition to this morphological heterogeneity at diagnosis, 
additional variability arises as significant tumour regression 
often occur already during the first 2-3 weeks of external 
beam radiotherapy (EBRT).  
Local tumour control in cervical cancer require significant 
dose which is achieved with the application of brachytherapy 
(BT), typically going from a dose level of about 45 Gy 
obtained with EBRT to a dose level of more than 90 Gy 
covering at least 90% of the target volume. Due to the steep 
dose gradients involved in BT even higher dose levels well 
above 100 Gy is then reached in the central part of the 
tumour.  
BT has traditionally been administered by use of fixed 
standard plans delivering certain doses to specific points 
defined in 2D in relation to the BT applicator (point-A) rather 
than adapted to the changing morphology of the cervix 
tumour. However, during the last decade a significant change 
in clinical practice has taken place towards using a dynamic 
target concept developed by the GEC ESTRO gynaecological 
working group. This 4D target concept enables the delivery of 
adaptive levels of BT dose to the tumour extension at both 
diagnosis (intermediate-risk CTV) and remaining tumour and 
cervix at time of BT (high-risk CTV). To obtain maximal 
advantage of the initial tumour regression during EBRT, but 
also to avoid deleterious repopulation, the application of BT 
is normally performed  during the final weeks of a 6-8 week 
overall treatment time. To fulfil the ambitious planning aims 
of reaching >90 Gy in the high-risk CTV and >60 Gy in the 
intermediate-risk CTV with out overdosing the near by organs 
at risk new application techniques for BT has been developed 
employing combined intracavitary-interstial applicators. In 
centres experienced in image guided BT the new 
intracavitary/interstitial technique is now employed in 
almost 50% of the patients. 
Single centre series with significant patient numbers have 
already demonstrated improved local control and survival 
with morphology adapted BT especially in large tumours even 
surpassing the effect found for concomitant cisplatin 15 years 
ago. In addition, the risk of severe urologic and gastro-
intestinal morbidity has been significantly reduced. 
Multicentre studies including quality of life endpoints are 
now maturing pointing to specific dose response curves for 
tumour control and dose effect curves for morbidity. These 
impending findings will further expand the therapeutic 
window in cervix cancer radiotherapy as these new principles 
for image guided BT with evidence based planning aims and 
constraints find their way into the clinics around the world. 
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Biologically individualized treatment by integration of 
biological data and respective adaptation of treatment is 
major field of research and has a great potential to prove the 
concept of personalized oncology to provide a benefit to 
patients. The potential benefit may result from descalation 
in patients with good-risk tumours, targeted escalation in 
intermediate-risk patients and assigning patients with high-
risk tumours to novel approaches to overcome radiation 
resistance. Innovations in functional imaging, biomarker 
research, data modelling, high-precision treatment planning 
and delivery within the context of better radiobiological 
understanding and careful consideration of established 
clinical factors enables translational and clincial research 
into dose painting, adaptation according to temporal changes 
and model-based treatment prescriptions.  
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Purpose/Objective: Image guided adaptive brachytherapy 
(IGABT), has transformed treatment for locally advanced 
cervical cancer considerably. Dose adaptation and combined 
intracavitary/interstitial (IC/IS) applicators have significantly 
changed dose and volume parameters for targets and organs 
at risk, resulting in improved outcomes. This study aimed to 
evaluate the impact of IC/IS brachytherapy on late morbidity 
on which, to date, there is little data. 
Materials and Methods: Seven hundred and thirty one 
patients with locally advanced cervical cancer were enrolled 
in the retroEMBRACE study from 12 institutions. Detailed 
information on grade 1-5 toxicity (CTCAE,V3.0) following 
IGABT was captured in 610 patients enrolled from 8 
institutions. These patients were analysed in the present 
study. Based on technique, patients were divided into two 
groups. One group (N=300) referred to as advanced adaptive 
(AD) included all patients from the empirical time point, 
when an institution used IC/IS technique systematically in 
more than 20% of the cases. The other group (N=310), 
referred to as limited adaptive (LA), included all other 
patients where the most frequent technique used was 
intracavitary. 
Results: Patient related factors such as age, FIGO stage, 
tumour width, lymph node status and follow up time were 
equally distributed between the groups. No difference in 
EBRT target volumes, doses and fractionation schedule was 
